ResMed Inc. (RMD.AX) Stock | RMD.AX Stock Price & Analysis

Feed

RMD.AX

ResMed Inc. RMD.AX ASX · Healthcare · United States

$34.98 +1.48% +$0.51

Summary

88 / 100 · Bulios Score

Valuation 49Growth 89Profitability 100Quality 94Debt 100Stability 100

What speaks for it

Out of every 100 USD of revenue, 28 USD is left as net profit.
Earnings per share grew by 21% a year over the last 3 years.
It earns 21 USD a year on every 100 USD of invested capital.
It holds more cash than debt: $1.01B against $608.9M.

What to watch

None of the indicators we track raises a caution right now.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Is it expensive?

Looks cheap

Bulios Fair Price

Undervalued Price today $34.98

By our assumptions the business is worth more than its shares cost today.

P/E today 21.1 30% lower

5-year average P/E 30.0

P/E today 21.1

Medical - Instruments & Supplies industry median

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 21.1 USD for 1 USD of yearly profit. Over the last five years it was 30.0 USD on average.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

3.6B

4.2B

4.7B

5.1B

5.8B

6.2B

2022202320242025202620272028

Diluted EPS (USD)

$0.50

$0.60

$0.70

$0.96

$1.07

$1.22

$1.33

2022202320242025202620272028

Analyst estimate

Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 11% a year. For the next fiscal year analysts expect revenue to grow by 1.1%. Earnings per share grew by 21% a year over the last 3 years.

Growth in detail

Does it make money?

Very well

Where 100 USD of revenue goes

Cost of sales 40 USD
Research and development 6.9 USD
Sales and administration 20 USD
Taxes and other 5.6 USD
Net profit 28 USD

Net profit, industry median (Medical - Instruments & Supplies) 8.5 USD

Out of every 100 USD of revenue, 28 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

Cash and short-term investments $1.01B

Debt $608.9M

Free cash flow over 12 months $1.60B

It could repay all its debt from a single year of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

Small, safe

Yield: 0.54%
Paid out of profit: 11%

You receive $0.19 per share a year. The company covers the payout with ease.

Dividends in detail

What do analysts expect?

Mildly positive

Buy 15
Hold 8
Sell 2

No analyst has published a price target.

60% of the analysts recommend buying.

Analysts in detail